Mechanism of drug resistance in att drugs in tb full details for md exam answer 15 marks from this pdf and your data
cd /home/daytona/workspace/attachments/d0175496-bbb7-4a03-8be2-5df98cc2f9d8/ && python3 -c " import pdfplumber pdf_path = 'Sharma mohan latest_compressed-compressed (1).pdf' with pdfplumber.open(pdf_path) as pdf: print(f'Total pages: {len(pdf.pages)}') # Search for drug resistance content for i, page in enumerate(pdf.pages): text = page.extract_text() if text and ('resist' in text.lower() or 'isoniazid' in text.lower() or 'rifampicin' in text.lower() or 'katg' in text.lower() or 'inhA' in text.lower()): print(f'--- PAGE {i+1} ---') print(text[:3000]) print() " 2>&1 | head -500
"drug resistance" AND "tuberculosis" AND "mechanism"
cd "/home/daytona/workspace/attachments/d0175496-bbb7-4a03-8be2-5df98cc2f9d8/" && python3 -c " from pypdf import PdfReader reader = PdfReader('Sharma mohan latest_compressed-compressed (1).pdf') print('Total pages:', len(reader.pages)) # search for resistance pages for i, page in enumerate(reader.pages): text = page.extract_text() or '' if 'resist' in text.lower() or 'katG' in text or 'inhA' in text.lower() or 'rpoB' in text.lower(): print(f'=== PAGE {i+1} ===') print(text[:4000]) print() " 2>&1 | head -600
python3 -c " from pypdf import PdfReader reader = PdfReader('/home/daytona/workspace/attachments/d0175496-bbb7-4a03-8be2-5df98cc2f9d8/Sharma mohan latest_compressed-compressed (1).pdf') print('Total pages:', len(reader.pages)) # Chapter 42 is drug-resistant TB, chapter 43 is resistance surveillance # Let's find the pages for i in range(570, 650): text = reader.pages[i].extract_text() or '' if 'mechanism' in text.lower() or 'katG' in text or 'rpoB' in text.lower() or 'inhA' in text.lower() or 'resistance mechanism' in text.lower(): print(f'=== PAGE {i+1} ===') print(text[:5000]) print() " 2>&1 | head -1000
python3 -c " from pypdf import PdfReader reader = PdfReader('/home/daytona/workspace/attachments/d0175496-bbb7-4a03-8be2-5df98cc2f9d8/Sharma mohan latest_compressed-compressed (1).pdf') # Chapter 42 starts around page 579 of the textbook (page ~604-630 of PDF) # Let's find the exact pages for chapter 42 on drug-resistant TB for i in range(598, 635): text = reader.pages[i].extract_text() or '' if 'pathogenesis' in text.lower() or 'mechanism' in text.lower() or 'mutation' in text.lower(): print(f'=== PAGE {i+1} (book page {text[:50]}) ===') print(text[:5000]) print() " 2>&1 | head -800
python3 -c " from pypdf import PdfReader reader = PdfReader('/home/daytona/workspace/attachments/d0175496-bbb7-4a03-8be2-5df98cc2f9d8/Sharma mohan latest_compressed-compressed (1).pdf') # Get the early section of chapter 42 - drug resistance mechanisms for each drug for i in range(599, 610): text = reader.pages[i].extract_text() or '' print(f'=== PAGE {i+1} ===') print(text[:5000]) print() " 2>&1 | head -800
Mechanism of Drug Resistance in Anti-Tuberculosis (ATT) Drugs
I. Introduction
II. General Mechanisms of Resistance (Applicable to All ATT Drugs)
A. Traditional (Classical) Mechanism — Mutant Selection
- Erratic / incomplete therapy kills susceptible bacilli but allows pre-existing DR mutants to replicate
- Probability of simultaneous resistance to two drugs is infinitesimally small (product of individual mutation rates), explaining why combination therapy prevents MDR
- Programme-related factors: drug shortages, poor DST, non-standardised regimens, inadequate training
- Patient-related factors: non-adherence, default, irregular treatment
B. Pharmacokinetic (PK) Variability — Newer Understanding
- Drug resistance can develop even with excellent adherence (Sharma & Mohan, Chapter 42)
- PK mismatch: drugs with long half-lives (bedaquiline, clofazimine) may act as functional monotherapy during washout periods
- Sub-MIC (minimum inhibitory concentration) drug concentrations in hollow fibre system studies strongly correlate with resistance amplification
- Between-person variability in drug absorption/metabolism drives site-specific sub-therapeutic levels
C. Induction of Efflux Pumps
- Sub-therapeutic drug concentrations induce multi-drug efflux pumps early in treatment
- Efflux pumps confer low-level resistance/tolerance, protect bacilli during several replication rounds
- Act as a "gateway" for eventual high-level chromosomal mutations — termed the "antibiotic resistance arrow of time"
- Co-existence of efflux pumps and genetic mutations is well documented
D. Differential Drug Penetration into Lung Micro-compartments
- Different susceptibility profiles (hetero-resistance) found in isolates from different lesions in the same patient (cavity wall vs. peri-fibrotic margin vs. normal lung)
- Immunopathology in the lung drives within-person PK variability
- Granulomas and caseous cavities may act as pharmacological sanctuaries with sub-MIC drug concentrations
E. Genotype and Compensatory Mutations
- Certain Mtb strains have higher in vivo mutation rates (dysfunctional DNA repair)
- Resistance-encoding mutations associate with compensatory mutations elsewhere in the Mtb genome (WGS studies)
- Compensatory mutations may restore fitness cost of DR mutations, allowing efficient transmission
- May alter mycobacterial antigen specificity, affecting T-cell immune responses
F. Primary (Person-to-Person) Transmission
- In high-burden settings (e.g., South Africa, China), 80–90% of MDR-TB cases result from primary transmission rather than acquired resistance
- A minority of "super-spreaders" (<10–20% of patients) account for most transmission
- XDR-TB outbreaks (e.g., Tugela Ferry) are primarily transmission-driven, confirmed by WGS
III. Drug-Specific Mechanisms of Resistance
1. Isoniazid (INH)
| Aspect | Detail |
|---|---|
| Action | Inhibits mycolic acid synthesis; also affects nucleic acid biosynthesis, lipids, glycolysis |
| Active form | Prodrug — activated by KatG (catalase-peroxidase) to form isonicotinoyl radical |
| Primary resistance gene | katG mutations (especially Ser315Thr) — eliminate prodrug activation |
| Second mechanism | inhA mutations (enoyl-ACP reductase promoter) — overexpression of InhA bypasses INH-inhibition of mycolic acid synthesis; confers low-level resistance; cross-resistance with ethionamide |
| Other genes | ahpC (alkyl hydroperoxide reductase), ndh (NADH dehydrogenase), oxyR (oxidative stress regulator), kasA (β-ketoacyl-ACP synthase) |
| Clinical note | katG mutation → high-level resistance; inhA mutation → low-level resistance (can be overcome by high-dose INH) |
2. Rifampicin (RIF)
| Aspect | Detail |
|---|---|
| Action | Inhibits β-subunit of DNA-dependent RNA polymerase → blocks initiation of RNA chain formation |
| Resistance gene | rpoB mutations — most common in the 81-bp rifampicin resistance-determining region (RRDR) (codons 507–533) |
| Key mutations | His526Tyr, Ser531Leu account for >80% of rifampicin resistance |
| Significance | rpoB mutation is a surrogate marker for MDR-TB (detected by Xpert MTB/RIF) |
| Cross-resistance | Rifabutin may retain activity against some rpoB mutants |
3. Pyrazinamide (PZA)
| Aspect | Detail |
|---|---|
| Action | Prodrug; converted to pyrazinoic acid by PZase (pyrazinamidase); active only in acidic intracellular environment |
| Resistance gene | pncA mutations (pyrazinamidase gene) — loss of PZase activity prevents drug activation |
| Other mechanisms | Mutations in rpsA (ribosomal protein S1), panD (aspartate decarboxylase) |
| Note | DST for PZA is technically difficult (requires acidic pH); 90–97% of PZA-resistant strains have pncA mutations |
4. Ethambutol (EMB)
| Aspect | Detail |
|---|---|
| Action | Inhibits arabinosyl transferases involved in arabinogalactan synthesis (cell wall) |
| Resistance genes | embA, embB, embC mutations (arabinosyl transferase complex) |
| Key mutation | embB codon 306 mutation — most common; accounts for ~70% of ethambutol resistance |
| Note | EMB resistance alone is uncommon; often accompanies MDR-TB |
5. Streptomycin (SM)
| Aspect | Detail |
|---|---|
| Action | Binds 16S rRNA of 30S ribosomal subunit → inhibits protein synthesis |
| Resistance genes | rpsL (ribosomal protein S12) and rrs (16S rRNA) mutations |
| Mechanism | rpsL mutations at codons 43 and 88 → high-level resistance; rrs mutations → aminoglycoside cross-resistance |
6. Second-line Injectable Agents (Amikacin, Kanamycin, Capreomycin)
| Aspect | Detail |
|---|---|
| Action | Amikacin/Kanamycin: bind 16S rRNA → inhibit protein synthesis; Capreomycin: targets 16S and 23S rRNA |
| Resistance genes | rrs mutations (A1401G most common — high-level resistance to all aminoglycosides); tlyA mutations (capreomycin-specific); eis promoter mutations (kanamycin low-level resistance) |
| Cross-resistance | rrs A1401G → cross-resistance between amikacin, kanamycin, and capreomycin |
7. Fluoroquinolones (Ofloxacin, Moxifloxacin, Levofloxacin)
| Aspect | Detail |
|---|---|
| Action | Inhibit DNA gyrase (topoisomerase II) and topoisomerase IV → block DNA replication |
| Resistance genes | gyrA and gyrB (DNA gyrase subunits) — mutations in Quinolone Resistance-Determining Region (QRDR) |
| Key mutations | gyrA codons 90 and 94 — most common |
| Note | Moxifloxacin retains activity against ofloxacin-resistant isolates (important for XDR-TB treatment) |
8. Ethionamide (Eto)
| Aspect | Detail |
|---|---|
| Resistance | inhA promoter mutations (shared with INH low-level resistance) → cross-resistance between INH and ethionamide; also ethA mutations |
IV. Types of Drug Resistance
| Type | Definition |
|---|---|
| Primary resistance | Resistance in a patient never previously treated for TB (transmitted DR strain) |
| Acquired (secondary) resistance | Resistance developing during treatment due to inadequate regimen/non-adherence |
| MDR-TB | Resistance to at least INH + RIF |
| Pre-XDR-TB (WHO 2021) | MDR/RR-TB + resistance to any fluoroquinolone |
| XDR-TB | MDR-TB + resistance to fluoroquinolone + at least one second-line injectable (amikacin/kanamycin/capreomycin) |
| TDR-TB | Resistance to all tested ATT drugs |
| Hetero-resistance | Different susceptibility profiles in isolates from different lung lesions in the same patient |
V. The Bacteriological Basis (Why Combination Therapy Prevents Resistance)
- In a cavity (bacterial load ~10⁸), spontaneous INH-resistant mutants occur at rate 1/10⁸ → ~1 resistant organism
- Spontaneous RIF-resistant mutants at rate 1/10⁸ → ~1 resistant organism
- Probability of simultaneous INH + RIF resistance = 1/10⁸ × 1/10⁸ = 1/10¹⁶ — clinically negligible
- Hence, combination therapy prevents emergence of resistance by multiple independent drug mechanisms acting simultaneously
VI. Clinical Implications
- Universal DST — every TB case should undergo DST for at least rifampicin resistance (Xpert MTB/RIF)
- Line Probe Assays (LPA) — MTBDRplus detects katG and inhA mutations; guides dosing (high-dose INH for inhA mutations)
- Therapeutic Drug Monitoring (TDM) — to address PK variability and sub-therapeutic levels
- Pharmacogenomics — identifying patient genotypes with rapid drug metabolism mandating TDM
- High-dose INH — overcomes inhA-mediated low-level resistance
- Avoid functional monotherapy — especially with long-half-life drugs (bedaquiline, clofazimine)
- Whole Genome Sequencing (WGS) — identifies resistance mutations, compensatory mutations, and tracks outbreaks
VII. Summary Table — Key Resistance Mutations
| Drug | Gene(s) | Mechanism |
|---|---|---|
| INH | katG, inhA, ahpC, ndh, kasA | Loss of prodrug activation; overexpression of target |
| RIF | rpoB | Altered RNA polymerase β-subunit |
| PZA | pncA, rpsA, panD | Loss of pyrazinamidase; altered target |
| EMB | embA, embB, embC | Altered arabinosyl transferase |
| SM | rpsL, rrs | Altered 30S ribosomal target |
| Aminoglycosides | rrs, eis, tlyA | Altered rRNA; drug inactivation |
| Fluoroquinolones | gyrA, gyrB | Altered DNA gyrase |
| Ethionamide | inhA, ethA | Shared INH resistance; altered activation |
- Chapter 42 (Dheda et al.): Pathogenesis of DR-TB — Table 42.2, Figure 42.3 (Pathogenesis diagram), pp. 579–607
- Chapter 44 (Singla et al.): Table 44.2 — Mechanism of action and genes involved in resistance for first-line drugs, p. 622
- Chapter 43 (Paramasivan, Balasangameshwara): ATT drug resistance surveillance, pp. 609–620
Recent Evidence Note: A 2025 review (Sikandar & Xing, Microb Pathog 2025; PMID: 40609770) confirms the above mechanisms and highlights emerging resistance to newer agents (bedaquiline: atpE mutations; linezolid: rrl, rplC mutations), consistent with Sharma & Mohan's framework.